Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Holocene Critical Zone dynamics in an Alpine catchment inferred from a speleothem multiproxy record: disentangling climate and human influences.

Regattieri E, Zanchetta G, Isola I, Zanella E, Drysdale RN, Hellstrom JC, Zerboni A, Dallai L, Tema E, Lanci L, Costa E, Magrì F.

Sci Rep. 2019 Nov 28;9(1):17829. doi: 10.1038/s41598-019-53583-7.

2.

Aborted propagation of the Ethiopian rift caused by linkage with the Kenyan rift.

Corti G, Cioni R, Franceschini Z, Sani F, Scaillet S, Molin P, Isola I, Mazzarini F, Brune S, Keir D, Erbello A, Muluneh A, Illsley-Kemp F, Glerum A.

Nat Commun. 2019 Mar 21;10(1):1309. doi: 10.1038/s41467-019-09335-2.

3.

Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.

Jiménez-Segura R, Granell M, Gironella M, Abella E, García-Guiñón A, Oriol A, Cabezudo E, Clapés V, Soler JA, Escoda L, López-Pardo J, Fernández de Larrea C, Cibeira MT, Tovar N, Isola I, Bladé J, Rosiñol L; GEMMAC (Grup per l l'estudi del mieloma mútiple i l'amiloïdosi de Catalunya).

Eur J Haematol. 2019 May;102(5):389-394. doi: 10.1111/ejh.13217. Epub 2019 Feb 25.

PMID:
30719772
4.

Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.

Díaz-Ricart M, Isola IM, Escolar G.

Drugs Today (Barc). 2018 Oct;54(10):591-600. doi: 10.1358/dot.2018.54.10.2869771. Review.

PMID:
30398480
5.

The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor.

Fernández de Larrea C, Isola I, Pereira A, Cibeira MT, Bladé J, Rosiñol L.

Leukemia. 2018 Sep;32(9):2082-2094. doi: 10.1038/s41375-018-0156-3. Epub 2018 May 23. No abstract available.

PMID:
29795240
6.

Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma.

Lozano E, Díaz T, Mena MP, Suñe G, Calvo X, Calderón M, Pérez-Amill L, Rodríguez V, Pérez-Galán P, Roué G, Cibeira MT, Rosiñol L, Isola I, Rodríguez-Lobato LG, Martin-Antonio B, Bladé J, Fernández de Larrea C.

J Immunol. 2018 Apr 15;200(8):2581-2591. doi: 10.4049/jimmunol.1701622. Epub 2018 Mar 12.

7.

Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.

Tovar N, Rodríguez-Lobato LG, Cibeira MT, Magnano L, Isola I, Rosiñol L, Bladé J, Fernández de Larrea C.

Amyloid. 2018 Jun;25(2):79-85. doi: 10.1080/13506129.2018.1443439. Epub 2018 Feb 26.

PMID:
29482381
8.

Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.

Fernández de Larrea C, Isola I, Pereira A, Cibeira MT, Magnano L, Tovar N, Rodríguez-Lobato LG, Calvo X, Aróstegui JI, Díaz T, Lozano E, Rozman M, Yagüe J, Bladé J, Rosiñol L.

Leukemia. 2018 Jun;32(6):1427-1434. doi: 10.1038/s41375-018-0013-4. Epub 2018 Feb 2.

PMID:
29463830
9.

Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.

Rodríguez-Lobato LG, Fernández de Larrea C, Cibeira MT, Tovar N, Isola I, Aróstegui JI, Rosiñol L, Díaz T, Lozano E, Yagüe J, Bladé J.

Amyloid. 2017 Dec;24(4):245-252. doi: 10.1080/13506129.2017.1390451. Epub 2017 Oct 20.

PMID:
29052436
10.

Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma.

Fernández de Larrea C, Dávila J, Isola I, Ocio EM, Rosiñol L, García-Sanz R, Cibeira MT, Tovar N, Rovira M, Mateos MV, Miguel JS, Bladé J.

Bone Marrow Transplant. 2017 Apr;52(4):567-569. doi: 10.1038/bmt.2016.299. Epub 2016 Nov 21.

PMID:
27869809
11.

Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.

Correa JG, Cibeira MT, Tovar N, Isola I, Pedrosa F, Díaz T, Lozano E, Magnano L, Rosiñol L, Bladé J, Fernández de Larrea C.

Br J Haematol. 2017 Dec;179(5):849-851. doi: 10.1111/bjh.14266. Epub 2016 Sep 8. No abstract available.

PMID:
27605200
12.

Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results.

Cervantes F, Isola IM, Alvarez-Larrán A, Hernández-Boluda JC, Correa JG, Pereira A.

Ann Hematol. 2015 Nov;94(11):1791-6. doi: 10.1007/s00277-015-2435-7. Epub 2015 Jun 28.

PMID:
26122869
13.

CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.

Finazzi MC, Carobbio A, Cervantes F, Isola IM, Vannucchi AM, Guglielmelli P, Rambaldi A, Finazzi G, Barosi G, Barbui T.

Leukemia. 2015 May;29(5):1209-10. doi: 10.1038/leu.2014.343. Epub 2014 Dec 8. No abstract available.

PMID:
25482134
14.

Evidence for obliquity forcing of glacial Termination II.

Drysdale RN, Hellstrom JC, Zanchetta G, Fallick AE, Sánchez Goñi MF, Couchoud I, McDonald J, Maas R, Lohmann G, Isola I.

Science. 2009 Sep 18;325(5947):1527-31. doi: 10.1126/science.1170371. Epub 2009 Aug 13. Erratum in: Science. 2009 Nov 6;326(5954):798.

15.

[Limitation of life-sustaining treatment. A prospective study in a clinical ward].

Novillo A, Ladenheim RI, Galante M, Isola IM, Musi ME, Naguel V, Rodríguez P.

Medicina (B Aires). 2008;68(6):437-41. Spanish.

PMID:
19147425
16.

Disseminated salmonellosis in a patient treated with temozolomide.

Georgescu G, Isola IM, Youssef S, Adachi J, Rolston K.

J Infect. 2008 Nov;57(5):414-5. doi: 10.1016/j.jinf.2008.06.021. Epub 2008 Aug 19.

PMID:
18715650
17.

[Liver function, hemostasis and reabsorption of urinary excreta in experimental enterocystoplasty].

Alberti C, Isola I, Ekema G.

Minerva Urol. 1971 Sep-Oct;23(5):187-92. Italian. No abstract available.

PMID:
4258067
18.

[Ileal bladder: urinary elimination and recirculation of radioactive tracers. Interpretative model].

Alberti C, Soana S, Isola I.

Minerva Urol. 1971 Jan-Feb;23(1):1-3. Italian. No abstract available.

PMID:
5568885

Supplemental Content

Support Center